The impact of Pgp-mediated drug resistance is well documented in oncology [12], particularly regarding tyrosine kinase inhibitors (TKIs) such as imatinib in chronic myeloid leukemia (CML) or others in [13]. This evidence concerns the gene PGP and chronic myelogenous leukemia, BCR-ABL1 positive.